We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
Read MoreHide Full Article
Key Takeaways
HIMS expands its care model with compounded and branded GLP-1s, menopause and low-testosterone programs.
HIMS boosts supply chain and diagnostics via acquisitions of a peptide facility and a lab business.
HIMS shifts semaglutide fulfillment to 503A pharmacies after FDA resolves shortage.
The renowned health and wellness platform, Hims & Hers Health, Inc.’s (HIMS - Free Report) , business model links virtual consultations directly to prescription access and home delivery. Customers meet with independent licensed providers through affiliated medical groups, and when medication is deemed appropriate, prescriptions are routed into a fulfillment network that includes in-house pharmacies, a 503B outsourcing facility and partner pharmacies. This setup supports both FDA-approved products and certain compounded offerings, so the telehealth visit and the medication shipment operate as one integrated care pathway.
Recent developments show HIMS’ integrated telehealth-and-prescription fulfillment model expanding while navigating tighter regulation. Access to weight-loss products now includes GLP-1 options that began with compounded injectable semaglutide and later added branded injectable semaglutide, but the FDA’s February 2025 resolution of the semaglutide shortage has constrained compounded supply and pushed fulfillment toward 503A pharmacies. Hims & Hers also completed acquisitions of a peptide manufacturing facility and a laboratory business, aimed at strengthening medication supply and diagnostics that feed into prescribed treatment.
On the specialty front, new programs deepen prescription-led telehealth. A menopause/perimenopause specialty offers provider-guided plans that may include estradiol and progesterone in pill, patch or cream forms, with treatment adjusted over time. Alongside this, a low-testosterone launch uses at-home lab testing plus personalized provider-directed therapies, reinforcing the loop from digital diagnosis to prescribed fulfillment.
LifeMD, Inc. (LFMD - Free Report) links virtual visits to prescription delivery through its direct-to-patient model. LifeMD sells subscriptions that combine telehealth access with prescribed medication, with medication treated as a distinct deliverable and often fulfilled by licensed mail-order partners. LifeMD enhanced this loop by operating an affiliated LifeMD Pharmacy and adding non-sterile compounding in September 2025. LifeMD also integrated with LillyDirect’s Gifthealth for Zepbound access and expanded pathways for cash-pay Wegovy and Ozempic prescriptions.
American Well Corporation (AMWL - Free Report) , popularly known as Amwell, supports telehealth tied to prescriptions by enabling clinicians to prescribe during virtual visits on its Converge platform. Amwell sells enterprise platform subscriptions to health plans and systems, and the company also earns visit fees when the Amwell Platform or Amwell Practice is used by clients or its affiliated medical group. The Converge experience gives providers workflows for notes and prescribing and uses FHIR (Fast Healthcare Interoperability Resources) interoperability to connect with clients’ electronic health records and apps. Amwell is accelerating the migration of visits to Converge.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 50.2% year to date, outperforming the industry’s growth of 10.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 3X is lower than the industry’s average of 5X, but is higher than its three-year median of 2.6X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
Image: Bigstock
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc.’s (HIMS - Free Report) , business model links virtual consultations directly to prescription access and home delivery. Customers meet with independent licensed providers through affiliated medical groups, and when medication is deemed appropriate, prescriptions are routed into a fulfillment network that includes in-house pharmacies, a 503B outsourcing facility and partner pharmacies. This setup supports both FDA-approved products and certain compounded offerings, so the telehealth visit and the medication shipment operate as one integrated care pathway.
Recent developments show HIMS’ integrated telehealth-and-prescription fulfillment model expanding while navigating tighter regulation. Access to weight-loss products now includes GLP-1 options that began with compounded injectable semaglutide and later added branded injectable semaglutide, but the FDA’s February 2025 resolution of the semaglutide shortage has constrained compounded supply and pushed fulfillment toward 503A pharmacies. Hims & Hers also completed acquisitions of a peptide manufacturing facility and a laboratory business, aimed at strengthening medication supply and diagnostics that feed into prescribed treatment.
On the specialty front, new programs deepen prescription-led telehealth. A menopause/perimenopause specialty offers provider-guided plans that may include estradiol and progesterone in pill, patch or cream forms, with treatment adjusted over time. Alongside this, a low-testosterone launch uses at-home lab testing plus personalized provider-directed therapies, reinforcing the loop from digital diagnosis to prescribed fulfillment.
LFMD & AMWL’s Telehealth-to-Prescription Platforms
LifeMD, Inc. (LFMD - Free Report) links virtual visits to prescription delivery through its direct-to-patient model. LifeMD sells subscriptions that combine telehealth access with prescribed medication, with medication treated as a distinct deliverable and often fulfilled by licensed mail-order partners. LifeMD enhanced this loop by operating an affiliated LifeMD Pharmacy and adding non-sterile compounding in September 2025. LifeMD also integrated with LillyDirect’s Gifthealth for Zepbound access and expanded pathways for cash-pay Wegovy and Ozempic prescriptions.
American Well Corporation (AMWL - Free Report) , popularly known as Amwell, supports telehealth tied to prescriptions by enabling clinicians to prescribe during virtual visits on its Converge platform. Amwell sells enterprise platform subscriptions to health plans and systems, and the company also earns visit fees when the Amwell Platform or Amwell Practice is used by clients or its affiliated medical group. The Converge experience gives providers workflows for notes and prescribing and uses FHIR (Fast Healthcare Interoperability Resources) interoperability to connect with clients’ electronic health records and apps. Amwell is accelerating the migration of visits to Converge.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 50.2% year to date, outperforming the industry’s growth of 10.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 3X is lower than the industry’s average of 5X, but is higher than its three-year median of 2.6X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.